Michael Gold

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease
    Michael Gold
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    J Clin Psychiatry 68:430-8. 2007
  2. ncbi Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study
    Michael Gold
    Neurosciences Medicines Development Center, GlaxoSmithKline, Stockley Park, Harlow, UK
    Dement Geriatr Cogn Disord 30:131-46. 2010
  3. ncbi Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials
    Michael C Irizarry
    WW Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, USA
    Clin J Pain 25:469-76. 2009
  4. ncbi SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
    Gareth Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Int J Geriatr Psychiatry 26:536-44. 2011
  5. ncbi Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reV
    Cecilia Linde
    Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
    Am Heart J 151:288-94. 2006
  6. ncbi Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease
    Henry Brodaty
    University of New South Wales, Sydney, Australia
    Dement Geriatr Cogn Disord 20:120-32. 2005
  7. ncbi Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
    Joel Schlessinger
    Advanced Skin Research Center, Omaha, NE, USA
    J Drugs Dermatol 6:607-15. 2007
  8. ncbi Tau therapeutics for Alzheimer's disease: the promise and the challenges
    Michael Gold
    Global Clinical Research and Development, CNS Analgesia, Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Mol Neurosci 19:331-4. 2002
  9. ncbi Overview of the Alliance for Cellular Signaling
    Alfred G Gilman
    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Nature 420:703-6. 2002
  10. ncbi Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank
    Warren W Barker
    Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
    Alzheimer Dis Assoc Disord 16:203-12. 2002

Collaborators

  • Suzanne Craft
  • Gary Landreth
  • Boris A Chizh
  • M C Irizarry
  • William T Abraham
  • H Brodaty
  • David Loewenstein
  • Cecilia Linde
  • Gilberto R Sambrano
  • Gareth Maher-Edwards
  • Joel Schlessinger
  • Alfred G Gilman
  • Warren W Barker
  • Pauline Williams
  • Gemma Jacobs
  • Ruth Dixon
  • Jo Hunter
  • Gillian Hopton
  • Jackie Hunter
  • Mitchell Wortzman
  • James Leyden
  • Lawrence Eichenfield
  • R Todd Plott
  • Alan Menter
  • Craig Leonardi
  • Murray Todd
  • Alice Kashuba
  • Roger Y Tsien
  • John Doyle
  • Carol Waters
  • Jen Liou
  • Melanie H Cobb
  • Melvin I Simon
  • Jack E Dixon
  • Martin A Schmidt
  • Jeffrey S Forrester
  • David Botstein
  • Lewis C Cantley
  • Bayard Miller
  • Shaun R Coughlin
  • Richard H Scheuermann
  • Dennis Mock
  • Elliott M Ross
  • Henry R Bourne
  • Bruce A Harris
  • Rama Ranganathan
  • Dylan G Harwood
  • Ronald Taussig
  • Eric N Olson
  • Paul W Sternberg
  • Hongjun Shu
  • Deirdre Brekken
  • Ranjan Duara
  • Joshua Li
  • Dianne DeCamp
  • Grischa Chandy
  • Tamara Roach
  • Stephen B Milne
  • James E Ferrell
  • Robert Hsueh
  • Tony Hunter
  • Michael J Berridge
  • Jason G Cyster
  • Brian Saunders
  • Donald Hilgemann
  • Yingming Zhao
  • Yuhong Ning
  • William E Seaman
  • Rochelle Long
  • Patrick J Casey
  • Paul C Sternweis
  • Madhusudan Natarajan
  • Heping Han
  • Joan S Brugge
  • Won Do Heo
  • Neil Graff-Radford
  • Temple F Smith
  • Yan Ni
  • Shankar Subramaniam
  • James T Stull
  • Iain Fraser
  • Arthur Weiss
  • Marc C Mumby
  • Cheryl A Luis
  • Steven Sevush
  • H Alex Brown
  • Dennis Dickson
  • Mary Verghese
  • Pavlina Ivanova
  • Douglas Newland

Detail Information

Publications10

  1. ncbi Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease
    Michael Gold
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    J Clin Psychiatry 68:430-8. 2007
    ..To gain insight into factors affecting the rate of decline in placebo-treated subjects participating in Alzheimer's disease (AD) clinical trials...
  2. ncbi Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study
    Michael Gold
    Neurosciences Medicines Development Center, GlaxoSmithKline, Stockley Park, Harlow, UK
    Dement Geriatr Cogn Disord 30:131-46. 2010
    ..An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR...
  3. ncbi Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials
    Michael C Irizarry
    WW Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, USA
    Clin J Pain 25:469-76. 2009
    ..The 574 patients in the pooled lamotrigine treatment arms were used as a replication dataset...
  4. ncbi SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
    Gareth Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Int J Geriatr Psychiatry 26:536-44. 2011
    ..To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial...
  5. ncbi Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reV
    Cecilia Linde
    Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
    Am Heart J 151:288-94. 2006
    ..The effects of CRT on HF outcomes in patients with asymptomatic left ventricular dysfunction (ALVD) or mild HF remain to be determined...
  6. ncbi Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease
    Henry Brodaty
    University of New South Wales, Sydney, Australia
    Dement Geriatr Cogn Disord 20:120-32. 2005
    ....
  7. ncbi Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
    Joel Schlessinger
    Advanced Skin Research Center, Omaha, NE, USA
    J Drugs Dermatol 6:607-15. 2007
    ..Individual ingredients and the combination were well-tolerated. Among those treated with the combination formulation, discontinuation rates due to adverse events were 1% or less...
  8. ncbi Tau therapeutics for Alzheimer's disease: the promise and the challenges
    Michael Gold
    Global Clinical Research and Development, CNS Analgesia, Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Mol Neurosci 19:331-4. 2002
    ..The issues discussed in this article are not exhaustively dealt with in either scope or detail...
  9. ncbi Overview of the Alliance for Cellular Signaling
    Alfred G Gilman
    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Nature 420:703-6. 2002
    ..One goal is to catalyse complementary research in individual laboratories; to facilitate this, all alliance data are freely available for use by the entire research community...
  10. ncbi Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank
    Warren W Barker
    Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
    Alzheimer Dis Assoc Disord 16:203-12. 2002
    ..These estimates of the a priori probabilities of dementing disorders have implications for clinicians and researchers...